Upgrade to SI Premium - Free Trial

FibroBiologics (FBLG)

0.95 +0.02 (2.15%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

FibroBiologics begins phase 1/2 trial for diabetic foot ulcer therapy June 3, 2026 7:00 AM - StreetInsider FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers June 3, 2026 7:00 AM - StreetInsider FibroBiologics presents psoriasis data at dermatology meeting May 22, 2026 8:30 AM - StreetInsider FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting May 22, 2026 8:30 AM - StreetInsider FibroBiologics files patent for oral fibroblast drug delivery May 18, 2026 8:30 AM - StreetInsider FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics May 18, 2026 8:30 AM - Globe NewsWire FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus May 11, 2026 8:30 AM - Globe NewsWire Form 8-K FibroBiologics, Inc. For: May 05 May 6, 2026 7:03 AM - SEC Filing Form 424B5 FibroBiologics, Inc. May 6, 2026 6:02 AM - SEC Filing FibroBiologics begins patient enrollment for diabetic foot ulcer trial May 5, 2026 8:31 AM - StreetInsider FibroBiologics CEO Issues Letter to Shareholders May 5, 2026 8:30 AM - Globe NewsWire Form 8-K FibroBiologics, Inc. For: May 04 May 5, 2026 7:21 AM - SEC Filing Form ARS FibroBiologics, Inc. For: Dec 31 May 5, 2026 7:20 AM - SEC Filing Form DEFA14A FibroBiologics, Inc. May 5, 2026 7:19 AM - SEC Filing Form DEF 14A FibroBiologics, Inc. For: May 05 May 5, 2026 7:18 AM - SEC Filing Form 4 FibroBiologics, Inc. For: May 04 Filed by: O'HEERON PETE May 4, 2026 7:01 PM - SEC Filing Form 4 FibroBiologics, Inc. For: May 04 Filed by: Khoja Hamid May 4, 2026 7:01 PM - SEC Filing Form 4 FibroBiologics, Inc. For: May 04 Filed by: Davis Jason May 4, 2026 7:01 PM - SEC Filing Form 4 FibroBiologics, Inc. For: May 04 Filed by: GARCIA RUBEN A May 4, 2026 7:00 PM - SEC Filing FibroBiologics reports burn wound treatment shows promise in preclinical study May 4, 2026 4:01 PM - StreetInsider FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring May 4, 2026 4:01 PM - StreetInsider FibroBiologics releases CYWC628 drug product for diabetic foot ulcer trial May 4, 2026 8:30 AM - StreetInsider FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial May 4, 2026 8:30 AM - Globe NewsWire Maxim Group Downgrades FibroBiologics (FBLG) to Hold May 4, 2026 8:12 AM - StreetInsider Form 424B5 FibroBiologics, Inc. May 1, 2026 4:04 PM - SEC Filing Form 8-K FibroBiologics, Inc. For: May 01 May 1, 2026 4:01 PM - SEC Filing FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update April 30, 2026 5:55 PM - Globe NewsWire Form 10-Q FibroBiologics, Inc. For: Mar 31 April 30, 2026 5:20 PM - SEC Filing FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026 April 30, 2026 8:30 AM - StreetInsider Form PRE 14A FibroBiologics, Inc. For: Apr 22 April 22, 2026 4:36 PM - SEC Filing Form 8-K FibroBiologics, Inc. For: Mar 09 April 20, 2026 4:16 PM - SEC Filing FibroBiologics meets NASDAQ listing requirements April 20, 2026 4:02 PM - StreetInsider FibroBiologics Compliant with All Nasdaq Listing Requirements April 20, 2026 4:01 PM - StreetInsider Form 8-K FibroBiologics, Inc. For: Apr 16 April 17, 2026 4:05 PM - SEC Filing FibroBiologics (FBLG) PT Raised to $8 at H.C. Wainwright April 16, 2026 10:20 AM - StreetInsider FibroBiologics presents thymic organoid data at aging conference April 10, 2026 8:32 AM - StreetInsider FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity April 10, 2026 8:30 AM - Globe NewsWire Form 8-K/A FibroBiologics, Inc. For: Apr 03 April 9, 2026 5:20 PM - SEC Filing Form SCHEDULE 13G FibroBiologics, Inc. Filed by: Lind Global Fund III LP April 9, 2026 4:31 PM - SEC Filing FibroBiologics terminates Texas sublease early, saves $0.8 million April 9, 2026 4:20 PM - StreetInsider Form 8-K FibroBiologics, Inc. For: Apr 03 April 9, 2026 4:16 PM - SEC Filing Form 8-K FibroBiologics, Inc. For: Mar 30 April 3, 2026 4:03 PM - SEC Filing Form 8-K FibroBiologics, Inc. For: Mar 31 April 2, 2026 4:05 PM - SEC Filing FibroBiologics completes $3 million public offering April 2, 2026 4:01 PM - StreetInsider FibroBiologics Announces Closing of $3 Million Public Offering April 2, 2026 4:01 PM - StreetInsider Form 424B4 FibroBiologics, Inc. April 1, 2026 4:19 PM - SEC Filing Form EFFECT FibroBiologics, Inc. April 1, 2026 6:07 AM - SEC Filing FibroBiologics prices $3 million public offering at $1.32 per share March 31, 2026 8:00 PM - StreetInsider FibroBiologics Announces Pricing of $3 Million Public Offering March 31, 2026 8:00 PM - StreetInsider FibroBiologics completes manufacturing of drug for diabetic foot ulcer trial March 31, 2026 4:21 PM - StreetInsider FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial March 31, 2026 4:15 PM - StreetInsider Form S-1 FibroBiologics, Inc. March 27, 2026 5:20 PM - SEC Filing D. Boral Capital Downgrades FibroBiologics (FBLG) to Hold March 26, 2026 7:03 AM - StreetInsider FibroBiologics announces 1-for-20 reverse stock split effective March 30 March 25, 2026 4:30 PM - StreetInsider FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement March 25, 2026 4:30 PM - StreetInsider The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed March 18, 2026 11:30 AM - StreetInsider Form 10-K/A FibroBiologics, Inc. For: Dec 31 March 13, 2026 4:21 PM - SEC Filing Full Article List